Richard Marsden
Chief Executive Officer bei SYNAIRGEN PLC
Vermögen: 64 088 $ am 31.03.2024
Profil
Richard James Marsden is currently the Chief Executive Officer & Executive Director at Synairgen Plc since 2009.
He is also a Director at Synairgen Research Ltd.
since 2004.
Previously, he worked as the Respiratory Director at MedImmune Ltd.
He was the Managing Director at Southampton Asset Management Ltd.
from 2005 to 2014.
Before that, he served as the Manager-Cystic Fibrosis Business Development at Respironics Ltd.
from 1998 to 2003.
Bekannte Unternehmensbeteiligungen
Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
---|---|---|---|---|
SYNAIRGEN PLC
0,49% | 31.12.2022 | 995 771 ( 0,49% ) | 64 088 $ | 31.03.2024 |
Aktive Positionen von Richard Marsden
Unternehmen | Position | Beginn |
---|---|---|
SYNAIRGEN PLC | Chief Executive Officer | 01.06.2004 |
Synairgen Research Ltd.
Synairgen Research Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Synairgen Plc, Synairgen Research Ltd. is a British company that engages in respiratory biology and develops novel therapies. The private company is based in Southampton, UK. Synairgen Research was founded in 2003. | Director/Board Member | 07.06.2004 |
Ehemalige bekannte Positionen von Richard Marsden
Unternehmen | Position | Ende |
---|---|---|
Southampton Asset Management Ltd.
Southampton Asset Management Ltd. Investment ManagersFinance Southampton Asset Management Ltd (SAM) is a venture capital firm, a subsidiary of University of Southampton Holdings Ltd. The firm is headquartered in Southampton, United Kingdom. | Director/Board Member | 17.03.2014 |
Respironics Ltd.
Respironics Ltd. Financial ConglomeratesFinance Respironics Ltd. develops and manufactures medical and healthcare products. Its products include Porta-Neb, Freeway Freedom, Sidestream, and Ventstream. The company was founded in 1977 and is headquartered in Bognor Regis, the United Kingdom. | Corporate Officer/Principal | 01.01.2003 |
MedImmune Ltd.
MedImmune Ltd. BiotechnologyHealth Technology MedImmune Ltd. engages in research, development and exploitation of products in the field of molecular engineering. The company was founded on December 11, 1989 and is headquartered in Cambridge, the United Kingdom. | Corporate Officer/Principal | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
SYNAIRGEN PLC | Health Technology |
Private Unternehmen | 4 |
---|---|
MedImmune Ltd.
MedImmune Ltd. BiotechnologyHealth Technology MedImmune Ltd. engages in research, development and exploitation of products in the field of molecular engineering. The company was founded on December 11, 1989 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
Respironics Ltd.
Respironics Ltd. Financial ConglomeratesFinance Respironics Ltd. develops and manufactures medical and healthcare products. Its products include Porta-Neb, Freeway Freedom, Sidestream, and Ventstream. The company was founded in 1977 and is headquartered in Bognor Regis, the United Kingdom. | Finance |
Southampton Asset Management Ltd.
Southampton Asset Management Ltd. Investment ManagersFinance Southampton Asset Management Ltd (SAM) is a venture capital firm, a subsidiary of University of Southampton Holdings Ltd. The firm is headquartered in Southampton, United Kingdom. | Finance |
Synairgen Research Ltd.
Synairgen Research Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Synairgen Plc, Synairgen Research Ltd. is a British company that engages in respiratory biology and develops novel therapies. The private company is based in Southampton, UK. Synairgen Research was founded in 2003. | Commercial Services |